Enzalutamide,Relacorilant
Corcept Therapeutics,pfizer,Astellas
['crpc', 'gu ', 'relacorilant']
come review results of our phase 1 safety trial of combined ar (enza) + selective gr (relacorilant) in mcrpc (n=35). combo was safe, rp2d determined &amp; prelim antitumor activity noted. abstract #5062 @ the gu poster session (hall a) today from 8-11 am. #asco23 
dad x2 | oncology Fellow @uchicago | Ph1 trials | drug development | GU onc | biotech | IM @clevelandclinic | ex-Big Pharma @abbvie @baxter_intl | squash |